Biotec® HPV Vaccine
Data Analytics
Our papillomavirus (HPV) vaccines are vaccines that prevent infection by certain types of human papillomavirus (HPV) Available HPV vaccines protect against either two, four, or nine types of HPV. All HPV vaccines protect against at least HPV types 16 and 18, which cause the greatest risk of cervical cancer. It is estimated that HPV vaccines may prevent 70% of cervical cancer, 80% of anal cancer, 60% of vaginal cancer, 40% of vulvar cancer, and show more than 90% efficacy in preventing HPV-positive oropharyngeal cancers
The HPV vaccine has been shown to prevent cervical dysplasia from the high-risk HPV types 16 and 18 and provide some protection against a few closely related high-risk HPV types. However, there are other high-risk HPV types that are not affected by the vaccine. The protection against HPV 16 and 18 has lasted at least eight years after vaccination for Gardasil and more than nine years for Cervarix. It is thought that booster vaccines will not be necessary
Our Portfolio
Biotec Pharma benefits from a strong portfolio of hospital therapeutics.
Our range of therapeutics includes conditions in the areas of allergy, cardiology, oncology etc. We market and sell our range of niche hospital therapeutics across Europe and constantly aim to improve our portfolio
